NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD

NovaBay Pharmaceuticals, Inc.

2000 Powell Street
Suite 1150
Emeryville, CA 94608
United States

Full Time Employees21

Key Executives

Mr. Mark M. Sieczkarek M.B.A.Chairman, Chief Exec. Officer and Pres453.5kN/A62
Mr. Justin M. Hall Esq.Sr. VP and Gen. Counsel253.5kN/A39
Mr. Thomas J. Paulson M.B.A.Exec.386.76kN/A70
Mr. John J. McGovernChief Financial OfficerN/AN/AN/A
Mr. Glenn MoroVP of MarketingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Corporate Governance

NovaBay Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.